Drugs / TQH2929
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06433531 | Jun 2024 → Jul 2025 overdue | generalized pustular psoriasis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06156280 | Nov 2023 → Aug 2024 | psoriasis | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07314060 | Mar → Dec 2026 expected | generalized pustular psoriasis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQH2929 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07314060 ↗ |
| Modality | Monoclonal antibody | “TQH2929 injection is a humanized monoclonal antibody that interfering with the signal cascade.” NCT06156280 ↗ |
| Route | Intravenous | “Intravenous infusion, single dose” NCT07314060 ↗ |